Sign in to view content

Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial

Jason Hsu, MD

Video
Published 2021

Related

Real-World Evidence for Pneumatic Retinopexy in Patients With Primary Rhegmatogenous Retinal Detachment Meeting PIVOT Trial Criteria
Verena Juncal, MD
Annual Meeting Talks
2019
Retrospective Real-World Analysis of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Followed for 3 Years
Ehsan Rahimy, MD
Annual Meeting Talks
2022
Safety and Efficacy of SC Elamipretide to Treat Noncentral Geographic Atrophy: ReCLAIM-1 Results and Phase II ReCLAIM-2 Baseline Characteristics
David R Lally, MD
Annual Meeting Talks
2021

Category: AMD-Non-Neovascular

See more